
- Nutritional Outlook Vol. 29., No. 9
- Volume 29
- Issue 9
Infant Nutrition’s Next Phase: Function, Oversight, and Proof
Key Takeaways
- HMOs act as prebiotics metabolized by taxa such as B. infantis, but industrial-scale production relies on fermentation, with high costs, yield constraints, and optimization needs.
- Trial data support growth and tolerability noninferiority for HiMO-supplemented formulas, yet evidentiary gaps persist regarding clinically meaningful benefits, target populations, dosing, and durability.
A look at HMOs research, FDA oversight, and claims scrutiny as developments expand in the infant formula category.
Nutrition in the early stages of life is arguably crucial. Yet as developments in infant nutrition continue to broaden, more questions about clinical evidence and claims for ingredients begin to arise amid tightening regulatory oversight.
HMOs, or human milk oligosaccharides, are a part of infant nutrition, providing essential nutrients for gut and immune health.1 Scrutiny of supplementation with human-identical milk oligosaccharides has been sharpening. For instance, a 2026 review highlighted the limitations of evidence, such as heterogeneity of studies, on the ingredient’s potential benefits.2 Regulatory scrutiny of infant formula in general has also seen an increase, highlighting safety and claim substantiation. Innovation in infant nutrition has also expanded to include maternal supplementation as well.
HMOs: From Human Milk to Formula Ingredient
HMOs, which are complex carbohydrates, are not digested by infants but function as prebiotic molecules and are metabolized by certain “health-promoting” bacteria, including Bifidobacterium infantis (B. infantis), recently published studies explain.1,2 HMOs are the third largest component in human milk, and while breastfeeding is the preferred source of nutrition for newborns, supplementation with HMOs may be considered as an intervention if needed.
Chemical and enzymatic synthesis has not been able to produce HMOs at an industrial scale, a review of the history of HMOs explains, and HMOs are produced mainly through microbial fermentation, which can generate multiple variants. Synthetic variants including 2ʹ-fucosyllactose (2ʹ-FL), lacto-N-tetrasaccharide, and 3ʹ-sialyllactose have been in commercial infant formula for approximately 10 years. High cost of production and limited yields remain production challenges, however, and the various production processes have room for optimization, the authors state.
HMOs have been receiving authorization from regulatory bodies for inclusion in infant dietary supplementation since 2015, including from the US Food and Drug Administration (FDA), the European Food Safety Authority, and Food Standards Australia New Zealand.
What the Clinical Evidence Highlights
A review from 2026 examined 12 randomized clinical trials involving supplementation with human-identical milk oligosaccharides (HiMO), assessing the health outcomes in infants.2 The population of the trials spanned healthy infants, special populations, and young children. The authors noted that 2′ -fucosyllactose, alone or in combination with other HiMOs, was the most widely evaluated. All 12 trials confirmed the noninferiority of formula supplemented with HiMOs on growth and tolerability compared with control, the authors also stated.
Ultimately, the review highlighted the promising potential of HiMOs as an intervention for improving child health, but more research was needed for direct evidence on the nature of the benefits and impacts, the authors concluded. “Some growth improvements were noted in association with HiMO intervention in preterm infants and in infants with severe acute malnutrition,” they explained. “HiMO supplementation may be a promising intervention to improve child health, but due to the heterogeneity and limitations of the clinical trials that have been undertaken, many questions remain about the nature of the benefits and the specific populations who might benefit.” It should be noted that the studies were almost all industry-funded with different HiMOs used in different concentrations, including some with other added components such as probiotics.
Another research paper highlights information still unclear about HMOs and challenges remaining. Although findings from animal studies have supported the inclusion of HMOs in infant formulas, the authors explain, HMO quality has been significantly lower than in natural human breastmilk. Most studies also focus on interventions lasting weeks or months, they add. “Well-designed long-term and longitudinal studies are therefore critically needed to clarify the sustained effects of HMOs on host metabolism, immune development, and long-term health outcomes.”
Why Function Matters: Microbiome Data
While clinical outcomes for HMO supplementation have been mixed, researchers have also examined the effects of early feeding changes on gut microbial function. A 2026 exploratory study analyzed microbiome shifts in 125 infants during feeding transitions from breastmilk or formula to solid foods, around 4 to 6 months of age.3 The authors noted that different milk types were a major influence on microbiome development, specifically that formula-fed infants tended to demonstrate higher microbial diversity and richness compared with infants who were breastfed or mixed-fed.
“The study reveals consistent, early functional shifts in the gut microbiome with the onset of complementary feeding, highlighting the strong influence of feeding mode on microbial metabolism and underscoring the need to consider function alongside taxonomy in early-life microbiome research,” the authors concluded. Though the study did not include HMOs, it offers insights into tracking early infant nutrition support and microbiome development.
A Tougher Regulatory and Claims Environment
The regulatory environment surrounding the developments of infant nutrition has seen increased attention and reinforced oversight. In May 2026, FDA published results from what it described as the largest testing of infant formula for contamination to date, signaling scrutiny of formula safety data.4 The agency tested approximately 300 samples from 16 brands across powdered, ready-to-feed, and concentrated liquid products, finding that most had undetectable or very low levels of heavy metals and pesticides.
“We’re doing everything in our power to make sure our babies and infants have safe, high quality formula options that are backed by a resilient supply chain,” the FDA commissioner said. “The results of this study are encouraging. We will continue to advance formula innovation and safety for the millions of families who depend on it.” The agency also pointed to a planned roundtable on Operation Stork Speed, which was announced in March 2025 and aimed to increase options for safe and nutritious infant formula.
Claim substantiation has also come under scrutiny. As one example, in August, BBB National Programs’ National Advertising Division (NAD), a self-regulating body, addressed challenges brought against Kendamil infant formula.5 In particular, HMO claims were found to be unsubstantiated. Specifically, NAD found that the company’s advertising reasonably conveyed that its HMO blend supported immune health but that its evidence did not, and it recommended that the claims be discontinued. Kendal Nutricare Limited said it would comply with NAD’s recommendations.
On November 6, 2026, NAD announced it will refer Kendal to government and state agencies and to advertising platforms for review and possible enforcement action.6 Kendal elected not to participate in a compliance inquiry that began after Abbott raised concerns about nearly all of the originally challenged claims.
Beyond the Bottle: Maternal Probiotics
Expansion of infant nutrition support may include maternal supplementation. For example, in March, the probiotic formulation Prenatis from Lallemand received approval for health claims from Health Canada, including a claim for supporting healthy gut flora in newborns when mothers consume the supplement during breastfeeding.7 In a clinical trial funded by Lallemand and published in 2025, 180 pregnant women consumed the prebiotic blend for 12 weeks and continued the supplementation for up to 6 weeks postpartum.8
The primary outcome focused on infections in women, but additional outcomes covered infant infections and gut microbiota composition. “The benefits extend to their infants and include a shorter duration of infections, enhanced gut colonization by beneficial bacteria (especially Bifidobacteria), and the induction of a highly interconnected microbiota that is structured around key species, which may confer health benefits in early infancy and throughout life,” the authors concluded. “Since they lack exposure to the mother’s vaginal microbiota and may require additional support to initiate healthy microbiome establishment, infants born by C-section may benefit from probiotic intake in mothers during pregnancy and lactation to a larger extent than infants born vaginally.”
Company leadership emphasized that the research demonstrated the significance of breastfeeding as a way to transmit benefits from mother to infant.
Closing
As innovation in infant nutrition and HMOs continues to develop, the research and claims will remain under examination as well, with evolving regulatory expectations and an emphasis on substantiated claims. Taking these trends together, the next phase of infant nutrition may be decided by the innovations that best align in these parameters.
References
- Luo L, Yang B, Zhao J, et al. Human milk oligosaccharides in nutrition and health: the past, present, and future. Food Sci Hum Wellness. Published online September 29, 2026. doi:10.26599/FSHW.2026.9251224
- Shivakoti R, Laughton B, Mandell J, et al. Limited evidence of benefits from clinical trials of human-identical milk oligosaccharides for infants. Adv Nutr. 2026;17(3):100593. doi:10.1016/j.advnut.2026.100593
- Joos R, Das A, Ahern G, et al. Functional maturation of the infant gut microbiome during dietary transition in the first year of life. Sci Rep. Published online September 22, 2026. doi:10.1038/s41598-026-71325-4
- McEvoy E. FDA infant formula testing signals ongoing contaminant oversight. Nutritional Outlook. May 7, 2026. Accessed October 13, 2026.
https://www.nutritionaloutlook.com/view/fda-infant-formula-testing-signals-ongoing-contaminant-oversight - McEvoy E. NAD recommends changes to some Kendamil infant formula marketing claims. Nutritional Outlook. August 31, 2026. Accessed October 13, 2026.
https://www.nutritionaloutlook.com/view/nad-recommends-changes-kendamil-infant-formula-marketing-claims - BBB National Programs. National Advertising Division to Refer Kendal to Government Agencies and Advertising Platforms for Electing Not to Participate in Compliance Inquiry. November 6, 2026. Accessed November 9, 2026.
https://bbbprograms.org/media/newsroom/decisions/kendal-compliance - McEvoy E. Lallemand Health Solutions secures new Canadian health claims for Prenatis probiotic. Nutritional Outlook. March 13, 2026. Accessed October 13, 2026.
https://www.nutritionaloutlook.com/view/lallemand-health-solutions-secures-new-canadian-health-claims-for-prenatis-probiotic - Binda S, Chow-Shi-Yée M, El Salti S, et al. The effect of probiotics on health in pregnancy and infants: a randomized, double-blind, placebo-controlled trial. Nutrients. 2025;17(11):1825. doi:10.3390/nu17111825
Articles in this issue
Related to this article








